| Literature DB >> 22871616 |
Arwa Ishaq Al-Khayyat1, Mohammed Al-Anazi, Arjumand Warsy, Alejandro Vazquez-Tello, Abdullah Mohammed Alamri, Rabih Halwani, Abdullah Alangari, Abdurrahman Al-Frayh, Qutayba Hamid, Saleh Al-Muhsen.
Abstract
BACKGROUND AND OBJECTIVES: Genetic association studies have demonstrated that over 100 variants in target genes (including ADAM33) are associated with airway remodeling and hyper-responsiveness in different ethnic groups; however, this has never been evaluated in Arabic populations. The objective of this study was to determine whether ADAM33 polymorphisms that are associated with asthma in a population of asthmatic children from Saudi Arabia. DESIGN ANDEntities:
Mesh:
Substances:
Year: 2012 PMID: 22871616 PMCID: PMC6080986 DOI: 10.5144/0256-4947.2012.479
Source DB: PubMed Journal: Ann Saudi Med ISSN: 0256-4947 Impact factor: 1.526
Demographics, clinical data, medication and severity of the disease in asthmatic children patients.
| Asthmatic patients | Males (%) | Females (%) |
|---|---|---|
|
| ||
| Number of patients by gender | 70 (65.4) | 37 (34.6) |
| Mean of age (years) | 7.42 | 6.89 |
| Mean age of onset (months) | 53.8 | 42.3 |
| Mean frequency of asthma attack (months) | 3.9 | 3.6 |
| Cough | 68 (97.1) | 37 (100) |
| Wheezing | 69 (98.6) | 31 (83.8) |
| Chest tightness | 63 (90) | 30 (81.1) |
| Breathlessness | 3 (4.3) | 5 (13.5) |
| Allergy | 44 (62.8) | 22 (59.5) |
| β2-Adrenergic Agonists | 65 (92.8) | 35 (94.6) |
| Bronchodilators | 63 (90) | 35 (94.6) |
| Inhaled Corticosteroids | 65 (92.8) | 35 (94.6) |
| Anti-cholinergic agents | 65 (92.8) | 35 (94.6) |
| Leukotriene Modifiers | 47 (67.1) | 31 (83.8) |
| Mild Intermittent | 1 (1.4) | 1 (2.7) |
| Mild Persistent | 40 (57.1) | 31 (83.8) |
| Moderate Persistent | 22 (31.4) | 4 (10.8) |
| Severe Persistent | 7 (10) | 1 (2.7) |
P=.01,
P=.031 for the differences in the means between males and females.
For each parameter, quantities represent the number of subjects and its corresponding percentage value within parenthesis.
Genotype frequency distribution of ADAM33 T1, T2, ST+4 and S1 polymorphisms and its association with asthma.
| SNP | Best Genetic Model | Genotype frequency, number (%) | OR (95% CI) | AIC (BIC) | |||
|---|---|---|---|---|---|---|---|
| Genotype | Healthy | Asthmatic | |||||
|
| |||||||
| T1 | Dominant | A/A | 53 (61.6) | 38 (39.6) | 1.00 | .001 | 241 (251) |
| rs2280091 | A/G-G/G | 33 (38.4) | 58 (60.4) | 2.70 (1.46–5.01)a | |||
| T2 | Dominant | G/G | 52 (61.9) | 41 (43.6) | 1.00 | .008 | 238 (247) |
| rs2280090 | G/A-A/A | 32 (38.1) | 53 (56.4) | 2.28 (1.22–4.23)a | |||
| ST+4 | NA | A/A | 32 (53.3) | 48 (48.5) | 1.00 | 0.49 | 211 (221) |
| rs44707 | A/C-C/C | 28 (46.7) | 51 (51.5) | 1.26 (0.66–2.43) | |||
| S1 | NA | C/C | 80 (97.6) | 90 (93.8) | 1.00 | 0.28 | 244 (254) |
| rs3918396 | C/T | 2 (2.4) | 6 (6.2) | 2.38 (0.46–12.37) | |||
Analysis of allele frequencies adjusted by covariate gender, showing odds ratio (OR) and 95% confidence interval (CI) for the best fit model of SNP association with asthma. For each SNP, 4 models were tested, using the most frequent homozygous genotype as reference. The OR and CI for only the best fit genetic model are shown, selected by their lowest index criteria values (AIC and BIC). NA means None Available.
Genotype frequencies (%) of T2, T1, ST+4 and S1 polymorphisms in ADAM33 gene.
| SNP | Healthy (H) or Asthmatic (A) | Genotype frequency (%) | |||
|---|---|---|---|---|---|
|
| |||||
| T1 | A/A | A/G | G/G | ||
| H | 61.2 | 32.9 | 5.9 | .014 | |
| A | 39.2 | 49.5 | 11.3 | ||
| T2 | G/G | G/A | A/A | ||
| H | 61.9 | 29.8 | 8.3 | .031 | |
| A | 43.6 | 48.9 | 7.4 | ||
| ST+4 | A/A | A/C | C/C | ||
| H | 53.3 | 46.7 | 0 | .53 | |
| A | 49.0 | 45.9 | 5.1 | ||
| S1 | C/C | C/T | T/T | ||
| H | 97.6 | 2.4 | 0 | .22 | |
| A | 93.8 | 6.3 | 0 | ||
P value represents the differences in the genotype frequencies between healthy subjects (H) and asthmatic patients (A).
Interaction analysis of single SNP-gender, with genotypes nested within genders.
| SNP | Gender | Genotype | Genotype Frequency, number & (%) | OR (95% CI) | Global Interaction | |
|---|---|---|---|---|---|---|
| Healthy | Asthmatics | |||||
|
| ||||||
| T1 | F | A/A | 25 (55.5) | 11 (33.3) | 1 | .054 |
| A/G | 19 (42.2) | 16 (48.5) | 1.91 (0.7–5.10 | |||
| G/G | 1 (2.3) | 6 (18.2) | 13.6 (1.5–127.6) | |||
| M | A/A | 28 (68.3) | 27 (42.9) | 1 | ||
| A/G | 9 (22.0) | 31 (49.2) | 3.6 (1.4–8.9) | |||
| G/G | 4 (9.8) | 5 (7.9) | 1.3 (0.3–5.4) | |||
| T2 | F | G/G | 26 (59.1) | 11 (35.5) | 1 | .13 |
| G/A | 16 (36.4) | 16 (51.6) | 2.36 (0.9–6.3) | |||
| A/A | 2 (4.5) | 4 (12.9) | 4.7 (0.7–29.7) | |||
| M | G/G | 26 (65.0) | 30 (47.6) | 1 | ||
| G/A | 9 (22.5) | 30 (47.6) | 2.9 (1.2–7.2) | |||
| A/A | 5 (12.5) | 3 (4.8) | 0.5 (0.1–2.4) | |||
| ST+4 | F | A/A | 14 (45.2) | 17 (50.0) | 1 | .41 |
| A/C | 17 (54.8) | 14 (41.2) | 0.7 (.2–1.8) | |||
| C/C | 0 (0.0) | 3 (8.8) | NA | |||
| M | A/A | 18 (62.1) | 31 (47.7) | 1 | ||
| A/C | 11 (37.9) | 32 (49.2) | 1.7 (0.7–4.2) | |||
| C/C | 0 (0.0) | 2 (3.1) | NA | |||
| S1 | F | C/C | 42 (97.7) | 32 (97.0) | 1 | .61 |
| C/T | 1 (2.3) | 1 (3.0) | 1.3 (0.1–21.8) | |||
| T/T | 0 (0.0) | 0 (0.0) | NA | |||
| M | C/C | 38 (97.4) | 58 (92.1) | 1 | ||
| C/T | 1 (2.6) | 5 (7.9) | 3.3 (0.4–29.1) | |||
| T/T | 0 (0.0) | 0 (0.0) | NA | |||
indicates significance of odds ratios (OR) and confidence intervals (95% CI) for heterozygous and less frequent homozygous genotypes, compared to the most frequent homozygous genotype
Figure 1Genomic structure of ADAM33 and the location of the 4 SNPs genotype. The 22 exons are shown as boxes and designated by the letters A through V. The SNPs and allele frequencies in Saudi compared to other populations are shown in the table.